Literature DB >> 27885468

Staphylococcus lugdunensis infections, filling in the gaps: a 3-year retrospective review from a comprehensive cancer center.

Lior Nesher1,2, Jeffery Tarrand3, Roy F Chemaly4, Kenneth Vi Rolston4.   

Abstract

OBJECTIVE: Staphylococcus lugdunensis is considered to be more aggressive than other coagulase-negative staphylococci (CoNS). There are gaps in knowledge regarding the importance of isolating S. lugdunensis from different sources and in different patient subsets. Our objective was to describe the spectrum, clinical manifestations, and outcomes of infections caused by S. lugdunensis in patients with cancer.
METHODS: A retrospective review of all cancer patients from whom S. lugdunensis was isolated in a pure culture from clinically significant sites.
RESULTS: Between 2011 and 2014, 2263 CoNS were isolated, of them 45 S. lugdunensis were isolated in a pure culture and were included in this analysis. Only three patients were neutropenic. Skin and skin structure infections (SSSIs) occurred most often (36 cases) followed by five blood stream infections, one of which had destructive endocarditis and four infections at other sites. Of the 36 SSSIs, 29 were related to surgical or invasive procedures, and six of these involved an implanted medical device. All isolates were susceptible to vancomycin, 98% to levofloxacin and 89% to oxacillin. All patients responded to the therapy.
CONCLUSIONS: Cancer patients including those with neutropenia do not appear to have an increased frequency of infections caused by S. lugdunensis. SSSIs are predominant and are often associated with surgical procedures and/or implanted medical devices. Blood stream infections caused by S. lugdunensis are uncommon but may have an increased rate of serious complications such as endocarditis. Nevertheless, these organisms are generally susceptible to multiple classes of antimicrobial agents, and the overall response to therapy is high.

Entities:  

Keywords:  Cancer patients; Skin/skin structure infection; Staphylococcus lugdunensis

Mesh:

Substances:

Year:  2016        PMID: 27885468      PMCID: PMC5323324          DOI: 10.1007/s00520-016-3493-7

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  30 in total

1.  Unusually virulent coagulase-negative Staphylococcus lugdunensis is frequently associated with infective endocarditis: a Waikato series of patients.

Authors:  Michael Liang; Chris Mansell; Clyde Wade; Raewyn Fisher; Gerard Devlin
Journal:  N Z Med J       Date:  2012-05-11

2.  Emergence of oxacillin-resistant Staphylococcus lugdunensis carrying staphylococcal cassette chromosome mec type V in central Taiwan.

Authors:  Ting-Yu Yen; Yun-Ju Sung; Hsiao-Chuan Lin; Ching-Tien Peng; Ni Tien; Kao-Pin Hwang; Jang-Jih Lu
Journal:  J Microbiol Immunol Infect       Date:  2014-12-11       Impact factor: 4.399

3.  Methicillin-resistant Staphylococcus lugdunensis carrying SCCmec type V misidentified as MRSA.

Authors:  Eliezer Menezes Pereira; Ricardo Pinto Schuenck; Simone Aranha Nouér; Kátia Regina Netto Dos Santos
Journal:  Braz J Infect Dis       Date:  2011 May-Jun       Impact factor: 1.949

4.  Laboratory and clinical characteristics of Staphylococcus lugdunensis prosthetic joint infections.

Authors:  Neel B Shah; Douglas R Osmon; Hind Fadel; Robin Patel; Peggy C Kohner; James M Steckelberg; Tad Mabry; Elie F Berbari
Journal:  J Clin Microbiol       Date:  2010-02-24       Impact factor: 5.948

5.  Virulence factors among Staphylococcus lugdunensis are associated with infection sites and clonal spread.

Authors:  N Giormezis; F Kolonitsiou; A Makri; A Vogiatzi; M Christofidou; E D Anastassiou; I Spiliopoulou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-12-04       Impact factor: 3.267

6.  Clinical experience and microbiologic characteristics of invasive Staphylococcus lugdunensis infection in a tertiary center in northern Taiwan.

Authors:  Jung-Fu Lin; Chun-Wen Cheng; An-Jing Kuo; Tsui-Ping Liu; Chien-Chang Yang; Ching-Tai Huang; Ming-Hsun Lee; Jang-Jih Lu
Journal:  J Microbiol Immunol Infect       Date:  2014-02-14       Impact factor: 4.399

7.  Staphylococcus lugdunensis in several niches of the normal skin flora.

Authors:  L Bieber; G Kahlmeter
Journal:  Clin Microbiol Infect       Date:  2009-06-06       Impact factor: 8.067

8.  Shear-Resistant Binding to von Willebrand Factor Allows Staphylococcus lugdunensis to Adhere to the Cardiac Valves and Initiate Endocarditis.

Authors:  Laurens Liesenborghs; Marijke Peetermans; Jorien Claes; Tiago Rafael Veloso; Christophe Vandenbriele; Maarten Criel; Marleen Lox; Willy E Peetermans; Simon Heilbronner; Philip G de Groot; Thomas Vanassche; Marc F Hoylaerts; Peter Verhamme
Journal:  J Infect Dis       Date:  2016-01-06       Impact factor: 5.226

9.  Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001).

Authors:  Jennifer M Streit; Ronald N Jones; Helio S Sader; Thomas R Fritsche
Journal:  Int J Antimicrob Agents       Date:  2004-08       Impact factor: 5.283

10.  Staphylococcus lugdunensis: clinical spectrum, antibiotic susceptibility, and phenotypic and genotypic patterns of 39 isolates.

Authors:  C Hellbacher; E Törnqvist; B Söderquist
Journal:  Clin Microbiol Infect       Date:  2006-01       Impact factor: 8.067

View more
  2 in total

1.  Acute-onset endophthalmitis caused by Staphylococcus lugdunensis.

Authors:  Robert B Garoon; Darlene Miller; Harry W Flynn
Journal:  Am J Ophthalmol Case Rep       Date:  2017-12-24

2.  Role of the LytSR Two-Component Regulatory System in Staphylococcus lugdunensis Biofilm Formation and Pathogenesis.

Authors:  Sandrine Dahyot; Virginie Oxaran; Maïté Niepceron; Eddy Dupart; Stéphanie Legris; Laurie Destruel; Jennifer Didi; Thomas Clamens; Olivier Lesouhaitier; Yasmine Zerdoumi; Jean-Michel Flaman; Martine Pestel-Caron
Journal:  Front Microbiol       Date:  2020-01-24       Impact factor: 5.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.